Reduction of adhesions using controlled delivery of active oxygen inhibitors

• US 6,780,427 B2
• Filed: 07/27/1998
• Issued: 08/24/2004
• Est. Priority Date: 03/24/1995
• Status: Expired due to Term

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Baker, Keith, Coury, Arthur J.
• Primary Examiner(s): Page, Thurman K.
• Application Number:
  US09/123,137
• Publication Number:
  US 20010046503A1
• Time in Patent Office: 2,220 Days
• Field of Search: 424/400, 424/484, 424/489, 424/78.08, 514/2, 514/261, 514/944, 514/963, 514/579
• US Class Current: 424/450
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 38/446 Superoxide dismutase (1.15)
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SOD and other active oxygen inhibitors are directly applied in combination with a barrier material at local sites of tissue injury to prevent or decrease formation of adhesions and undesirable proliferation of cells. Preferred barrier materials are polymeric hydrogels providing controlled release of AOI which are directly applied to the afflicted tissue. Examples demonstrate the effects of SOD on pelvic adhesions in the rat when administered by intraperitoneal (I.P.) bolus and by localized sustained release from a topically applied hydrogel system.

Claims

1. A composition for the local alleviation of a medical condition caused by inflammation or unwanted tissue proliferation at a site, the composition comprising

an effective amount of one or more active oxygen inhibitor compounds which destroy or prevent the formation of active oxygen species in a polymer solution or hydrogel, wherein the polymer solution or hydrogel is administered to the site in a fluent form and forms a conforming barrier by ionic crosslinking, chemical redox reaction, photopolymerization, or physical gelation at the site of administration, and

wherein the barrier persists at the site for days to weeks.

2. The composition of claim 1, where the banier is degradable in vivo.

3. The composilion of claim 1, where the polymer solution is photopolymerizable.

4. The composition of claim 1, where the polymer solution or hydrogel comprises 0.5% to 80% by weight of the composition.

5. The composition of claim 4, where the polymer solution or hydrogel comprises 2% to 50% by weight of the composition.

6. The composition of claim 5, where the polymer solution or hydrogel comprises 4% to 30% by weight of the composition.

7. The composition of claim 1, where the active oxygen inhibitor compound is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

8. The composition of claim 7, where the inhibitor compound is superoxide dismutase.

9. The composition of claim 1 further comprising a biologically active compound other than an active oxygen inhibitor compound.

20. The composition of claim 1, where the proliferation to be inhibited is the formation of an adhesion.

21. The composition of claim 20, where the adhesion is a secondary adhesion.

22. The composition of claim 1, further comprising in the polymer solution or hydrogel controlled drug delivery means for controlling the rate of delivery of the active oxygen inhibitor.

10. A method for the prevention of local inflammation or tissue proliferation, comprising administering a comprising an effective amount of an active oxygen inhibitor compound which destroys or prevents the formation of active oxygen species in combination with a polymer solution or hydrogel, wherein the polymer solution or hydrogel is administered to the site in a fluent form and forms a conforming barrierby ionic crosslinking, chemical redox reaction, photopolymerization, or physical gelation at the site of administration, and wherein the barrier persists at the site for days to weeks.

11. The method of claim 10, further comprising administering the composition in a pharmaceutically acceptable vehicle.

12. The method of claim 10, where the proliferation to be inhibited is the formation of an adhesion.

13. The method of claim 12, where the adhesion is a secondary adhesion.

14. The method of claim 10, where in the active oxygen inhibitor compound is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

15. The method of claim 14, where the inhibitor compound is superoxide dismutese.

16. The method of claim 10, wherein the active oxygen inhibitor compound is administered in a controlled release formulation.

17. The method of claim 10, where the barrier-forming material is a hydrogel-forming polymer.

18. The method of claim 10, further comprising administering at the site biologically active molecules that are not active oxygen inhibitors.

19. The method of claim 10, wherein the controlled release formulation is separate from the polymer solution or hydrogel forming the barrier.